29
2024-04
Accropeutics Bioscience Announces Positive Results from its Phase I Clinical Trial Evaluating RIPK2 Kinase Inhibitor AC-101 in Healthy Human Subjects in Australia
MORE
25
2023-12
Accropeutics' RIPK1 inhibitor AC-003 capsule has been granted Orphan Drug Designation by the FDA
MORE
09
2023-09
Selective TYK2/JAK1 Inhibitor AC-201 gained National Medical Products Administration (NMPA) permission for Phase 1
MORE
26
2023-06
RIPK2 Inhibitor AC-101 has been approved by the National Medical Products Administration (NMPA) to conduct clinical trials for Healthy Human Subjects
MORE
12
2023-05
TYK2/JAK1 Inhibitor AC-201 gained Human Research Ethics Committees (HREC) permission for Phase I
MORE
08
2023-05
RIPK1 Inhibitor AC-003 has been approved by National Medical Products Administration (NMPA) to conduct clinical trials for aGVHD patients
MORE
13
2023-04
Accropeutics Bioscience Announces First-in-Human Dose of AC-101 in Phase 1 Clinical Trial in Australia
MORE
06
2023-03
RIPK2 Inhibitor AC-101 has been granted clinical trial permission by Human Research Ethics Committee (HREC)
MORE
08
2022-08
AC-003 has been granted clinical trial permission by Center For Drug Evaluation (CDE)
MORE
01
2022-05
AC-003 has been granted clinical trial permission by Food & Drug Administration (FDA)
MORE